Emicizumab

• CAT Number: I041852
• CAS Number: 1610943-06-0
• Purity: ≥95%

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research[1].
Emicizumab (1.5-10 mg/kg, IV, 24 hours before tail-clip bleeding) partially corrects blood loss in a hemophilia A bleeding model, with an FVIII equivalence of 9 U/dL[1].
Emicizumab (3 mg/kg, IV) provides additive hemostatic activity when given in combination with low-dose FVIII (10 U/dL)[1].

Reference

[1]. Ferrière S, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020 Aug 6;136(6):740-748.
 [Content Brief]